Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Adverse events = classified as related to the drug, for all patients during the study period

From: In vivo efficacy of artesunate–amodiaquine and artemether–lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo

  ASAQ (n = 144) AL (n = 144) Total p value
Asthenia 61 (42.4 %) 13 (9.0 %) 74 (25.7 %) <0.001
Anorexia 27 (18.8 %) 12 (8.3 %) 39 (13.5 %) 0.010
Vomiting 11 (7.6 %) 10 (6.9 %) 21 (7.3 %) 0.821
Cough 5 (3.5 %) 7 (4.9 %) 12 (4.2 %) 0.555
Abdominal Pain 6 (4.2 %) 2 (1.4 %) 8 (2.8 %) 0.151
Diarrhoea 4 (2.8 %) 2 (1.4 %) 6 (2.1 %) 0.409
Itching 3 (2.1 %) 1 (0.7 %) 4 (1.4 %) 0.314
Nausea 1 (0.7 %) 1 (0.7 %) 2 (0.7 %) 1.000